NCT01134055 - Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration | Biotech Hunter

Enrollment

510

Participants

Timeline

Start Date

June 1, 2010

Primary Completion Date

October 1, 2012

Study Completion Date

October 1, 2012

Conditions

Macular Degeneration

Interventions

DRUG

pazopanib eye drops

A tyrosine kinase inhibitor of multiple receptors including vascular endothelial growth factor receptors and platelet-derived growth factor receptors.

DRUG

placebo

placebo eye drops

BIOLOGICAL

ranibizumab intravitreal injection

Humanized recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A

Trial Locations (77)

1020

GSK Investigational Site, Brussels

2000

GSK Investigational Site, Sydney

2150

GSK Investigational Site, Sydney

4000

GSK Investigational Site, Liège

6009

GSK Investigational Site, Nedlands

10003

GSK Investigational Site, New York

10122

GSK Investigational Site, Turin

19107

GSK Investigational Site, Philadelphia

20132

GSK Investigational Site, Milan

20157

GSK Investigational Site, Milan

21287

GSK Investigational Site, Baltimore

24105

GSK Investigational Site, Kiel

27599

GSK Investigational Site, Chapel Hill

28210

GSK Investigational Site, Charlotte

28803

GSK Investigational Site, Asheville

33100

GSK Investigational Site, Udine

33880

GSK Investigational Site, Winter Haven

33901

GSK Investigational Site, Fort Myers

35128

GSK Investigational Site, Padua

42001

GSK Investigational Site, Paducah

43212

GSK Investigational Site, Columbus

44122

GSK Investigational Site, Beachwood

44130

GSK Investigational Site, Cleveland

44195

GSK Investigational Site, Cleveland

48073

GSK Investigational Site, Royal Oak

49686

GSK Investigational Site, Traverse City

53127

GSK Investigational Site, Bonn

53705

GSK Investigational Site, Madison

60612

GSK Investigational Site, Chicago

66211

GSK Investigational Site, Leawood

72076

GSK Investigational Site, Tübingen

75231

GSK Investigational Site, Dallas

76104

GSK Investigational Site, Fort Worth

78705

GSK Investigational Site, Austin

79106

GSK Investigational Site, Freiburg im Breisgau

80336

GSK Investigational Site, Munich

80401

GSK Investigational Site, Golden

84107

GSK Investigational Site, Salt Lake City

85014

GSK Investigational Site, Phoenix

85020

GSK Investigational Site, Phoenix

85381

GSK Investigational Site, Peoria

85704

GSK Investigational Site, Tucson

85710

GSK Investigational Site, Tucson

92064

GSK Investigational Site, Poway

92354

GSK Investigational Site, Loma Linda

92697

GSK Investigational Site, Irvine

92705

GSK Investigational Site, Santa Ana

97239

GSK Investigational Site, Portland

97520

GSK Investigational Site, Ashland

98104

GSK Investigational Site, Seattle

98383

GSK Investigational Site, Silverdale

02114

GSK Investigational Site, Boston

Unknown

GSK Investigational Site, Melbourne

GSK Investigational Site, Glostrup Municipality

V5Z 3N9

GSK Investigational Site, Vancouver

V8V 4X3

GSK Investigational Site, Victoria

B3H 2Y9

GSK Investigational Site, Halifax

N6A 4V2

GSK Investigational Site, London

L4W 1W9

GSK Investigational Site, Mississauga

M4N 3M5

GSK Investigational Site, Toronto

DK-8000

GSK Investigational Site, Aarhus

01307

GSK Investigational Site, Dresden

04103

GSK Investigational Site, Leipzig

460-0011

GSK Investigational Site, Aichi

462-0825

GSK Investigational Site, Aichi

466-8560

GSK Investigational Site, Aichi

279-0021

GSK Investigational Site, Chiba

812-8582

GSK Investigational Site, Fukuoka

960-1295

GSK Investigational Site, Fukushima

001-0016

GSK Investigational Site, Hokkaido

060-8604

GSK Investigational Site, Hokkaido

761-0793

GSK Investigational Site, Kagawa

101-8309

GSK Investigational Site, Tokyo

SE-581 85

GSK Investigational Site, Linköping

SE-701 85

GSK Investigational Site, Örebro

SE-112 82

GSK Investigational Site, Stockholm

SE-751 85

GSK Investigational Site, Uppsala